CC-223
Drug
Celgene Corporation
Total Payments
$313,818
Transactions
14
Doctors
7
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $4,912 | 1 | 0 |
| 2018 | $20,062 | 7 | 7 |
| 2017 | $288,844 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $296,622 | 8 | 94.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,196 | 6 | 5.5% |
Payments by Type
Research
$296,622
8 transactions
General
$17,196
6 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CC-223-ST-001 | Celgene Corporation | $249,556 | 0 |
| CC-223-NSCL-001 | Celgene Corporation | $39,288 | 0 |
| A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects with Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma (CC-223-ST-001) | Celgene Corporation | $4,912 | 0 |
| CC-223-ST-001 - A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subje | Celgene Corporation | $2,866 | 1 |
Top Doctors Receiving Payments for CC-223
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $293,756 | 7 |
| , M.D | Medical Oncology | New York, NY | $2,866 | 1 |
| , MD | Medical Oncology | San Antonio, TX | $2,866 | 1 |
| , MD | Hematology & Oncology | Tampa, FL | $2,866 | 1 |
| Amit Mahipal | Hematology & Oncology | Rochester, MN | $2,866 | 1 |
| , MD | Medical Oncology | San Antonio, TX | $2,866 | 1 |
| , MD | Medical Oncology | Toledo, OH | $2,866 | 1 |
| , M.D | Medical Oncology | Nashville, TN | $2,866 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $313,818
Product Information
- Type Drug
- Total Payments $313,818
- Total Doctors 7
- Transactions 14
About CC-223
CC-223 is a drug associated with $313,818 in payments to 7 healthcare providers, recorded across 14 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2019. In 2019, $4,912 was paid across 1 transactions to 0 doctors.
The most common payment nature for CC-223 is "Unspecified" ($296,622, 94.5% of total).
CC-223 is associated with 4 research studies, including "CC-223-ST-001" ($249,556).